Navigation Links
febit Receives U.S. Patent for Microfluidic Extraction Method
Date:5/27/2008

febit Expands its Leading Position in Next-Generation Sequencing

LEXINGTON, Mass. and HEIDELBERG, Germany, May 27 /PRNewswire/ -- febit today announced the receipt of US patent #7320862 on its microfluidic microarray-based method for extraction of DNA and RNA.

This method forms the basis of a novel technology that enables the expanded use of next-generation sequencers in genomic research. Further investigation of the human genome by resequencing will particularly benefit from the new method: febit uses its microfluidic biochip system for sequence-based selective isolation of nucleic acids from genomic samples. This new approach to high-throughput sequencing essentially relies on high-density microarray biochips with flexible design, a technology established by febit several years ago. The newly patented method is known as hybselect, targeted sequencing or sequence capture. Using this innovative technique, researchers are able to isolate genes or genomic regions of interest from a complex DNA sample prior to sequencing.

febit microfluidic biochip systems have been successfully used for several years in DNA analysis and synthesis. The latest patent was now granted in the US, patents in Europe and other foreign countries will soon follow.

febit currently holds more than 20 patents and patent applications. In addition to bioanalytics, the company's intellectual property portfolio predominantly covers the production of synthetic genes on biochips, an area where febit holds several key patents. Using a focussed application strategy, febit has been able to secure intellectual property rights on important product components, processes and evolving technologies.

About febit

febit enables scientists to read, write and understand the code of life: DNA. With its unique Geniom technology and services, febit is the only company that puts the control of simplified genomic research in the hand of the user. The seamless integration of DNA synthesis and analysis and the superior support in experiment design and bioinformatics helps to understand data and turn it into results. febit's team of experienced scientists is dedicated to support customers to solve the challenge of understanding biological processes. Geniom is a technological and service platform successfully implemented in basic and applied research by renowned institutions and companies. Geniom exploits cutting-edge microarray technology for analysis and synthesis of genes and genomes, providing superior time- and cost-efficiency combined with an unsurpassed spectrum of applications.
http://www.febit.com

Contact:

febit holding gmbh Russo Partners, LLC

Eva Sterzel David Schull or Wendy Lau

Public Relations Manager +1-212-845-4271

+49 (6221) 6510-300 david.schull@russopartnersllc.com

eva.sterzel@febit.de wendy.lau@russopartnersllc.com


'/>"/>
SOURCE febit
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. febit to Introduce Geniom RT Analyzer(R) to U.S. Market at RNAi World Congress
2. febit First to Offer miRBase 11.0 Biochip
3. febit Forms Scientific Advisory Board
4. febit Appoints Michelle Lyles, Ph.D., Vice President, Marketing and Sales
5. Prime Therapeutics Receives VIPPS Accreditation
6. Tasker Products Receives Authorization from USDA for its Tasker Clear for use in Meat and Pork Industries
7. Lentigen Corporation Receives Four Research Grants From the National Institutes of Health
8. Albert Einstein College of Medicine Receives $25-Million Gift to Support Stem Cell and Epigenomic Research and Clinical Skills Training
9. S*BIO Receives Orphan Drug Designation for JAK2 Inhibitor SB1518 for the Treatment of Myeloproliferative Disorders
10. Atrium Medical Receives FDA Approval for its Novel C-QUR Lite(TM) V-Patch and C-QUR Edge(TM) V-Patch
11. Nektar Receives Patent Covering Pulmonary Targeted Antibiotics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... February 12, 2016 MedGenome,s ... Enabling Scientific Understanding of Complex Diseases Such as ... --> --> ... Asia and a leading provider of genomics research ... million to the GenomeAsia 100K consortium as a ...
(Date:2/11/2016)... Feb. 11, 2016  Bioethics International, a not-for-profit organization focused ... developed, marketed and made accessible to patients around the world, ... had named the publication of the Good Pharma Scorecard ... is also featured as one of BMJ Open ,s ... year that are most frequently read. Ed Sucksmith ...
(Date:2/11/2016)... , February 11, 2016 ... ("PositiveID" or "Company") (OTCQB: PSID), a life sciences ... that its Thermomedics subsidiary, which markets the Caregiver® ... growth plan in January 2016, including entering into ... sequential monthly sales growth, and establishing several near-term ...
(Date:2/10/2016)... 2016 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), ... that Mitsui & Co. Ltd., its partner in the ... is investing an additional CDN$25 million in the joint ... from 30% to 40%.  Mitsui will also play a ... in Sarnia , providing dedicated resources ...
Breaking Biology Technology:
(Date:2/10/2016)... PUNE, India , February 10, 2016 ... --> According to 2016 iris ... fingerprint identification iris recognition is more widely ... are available with both fingerprint and iris ... allows the user to avoid purchasing two ...
(Date:2/4/2016)... , Feb. 4, 2016 The ... apparently one of the most popular hubs of ... MetaHIT and other huge studies of human microbiota, ... past few years, the microbiome space has literally ... biomedical research. This report focuses on biomedical ...
(Date:2/2/2016)... 2, 2016  BioMEMS devices deployed in ... on medical screening and diagnostic applications, such ... devices that facilitate and assure continuous monitoring ... are being bolstered through new opportunities offered ... acquisition coupled with wireless connectivity and low ...
Breaking Biology News(10 mins):